New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells

<table>Cellular mechanisms of metformin and sorafenib effects against GBM CSCs. Metformin and sorafenib selectively target CSCs from which GBMs develop, acting on three key features: self-renewal, tumorigenicity, and differentiation ability. Fading arrows mean that metformin and sorafenib restrain specific CSC features, while the green arrow depicts an induction towards CSC differentiation mediated by metformin and sorafenib.</table>

BioMed Research International

fig1

Figure 1

Figure 1: New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells 